Fresenius Kabi Receives FDA Approval for Neostigmine Methylsulfate Injection

LAKE ZURICH, Ill., January 19, 2015 – Fresenius Kabi, a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition, announced today it has received approval from the U.S. Food and Drug Administration to market Neostigmine Methylsulfate Injection.

This is the first Fresenius Kabi drug approved by the FDA since the agency upgraded the status of the company’s pharmaceutical manufacturing facility in Grand Island, N.Y., earlier this month. The company announced January 12 that the facility had achieved voluntary action indicated (VAI) status from the FDA. VAI classification permits FDA approval of new products to be manufactured at the plant.

Neostigmine Methylsulfate Injection, a cholinesterase inhibitor, is indicated for reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after surgery. Fresenius Kabi expects to begin offering Neostigmine Methylsulfate Injection later this year.

About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in lifesaving medicines and medical devices for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. For more information about Fresenius Kabi worldwide, please visit www.fresenius-kabi.com.

Contacts
Matt Kuhn
847-550-5751
matt.kuhn@fresenius-kabi.com